Cargando…

On the Bayesian Derivation of a Treatment-based Cancer Ontology

Traditional cancer classifications are primarily based on anatomical locations. As knowledge is heavily compartmentalized in the oncological specialties, discovering new targets for existing drugs (drug inference) can take years. Furthermore, our lack of understanding of the mechanisms underlying dr...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Michael, Warner, Jeremy, Yang, Peter, Alterovitz, Gil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Informatics Association 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4419756/
https://www.ncbi.nlm.nih.gov/pubmed/25954588
_version_ 1782369635466739712
author Gao, Michael
Warner, Jeremy
Yang, Peter
Alterovitz, Gil
author_facet Gao, Michael
Warner, Jeremy
Yang, Peter
Alterovitz, Gil
author_sort Gao, Michael
collection PubMed
description Traditional cancer classifications are primarily based on anatomical locations. As knowledge is heavily compartmentalized in the oncological specialties, discovering new targets for existing drugs (drug inference) can take years. Furthermore, our lack of understanding of the mechanisms underlying drug efficacy sometimes undercuts the effectiveness of genetic approaches to drug inference. This study tackles the twin problems of cancer reclassification and drug inference by constructing a global cancer ontology inductively from treatment regimens. A topological abstraction algorithm was performed on the bipartite graph of drugs and cancers to highlight important edges, and a Bayesian algorithm was then applied to determine a new treatment-based classification of cancer, producing 6 highly significant clusters (p < 0.05), confirmed by Fisher’s exact test and enrichment analyses. Edge probabilities derived from its drug inference routine matched real edge frequencies (R2 ≈ 0.96). Drug inference results were reinforced by the identification of relevant published Phase II and III clinical trials, and the drug inference routine differentiated between high- and low-likelihood targets (p < 0.05). This novel treatment-based ontology has the potential to reorganize cancer research and provide powerful tools for drug inference using global patterns of drug efficacy.
format Online
Article
Text
id pubmed-4419756
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher American Medical Informatics Association
record_format MEDLINE/PubMed
spelling pubmed-44197562015-05-07 On the Bayesian Derivation of a Treatment-based Cancer Ontology Gao, Michael Warner, Jeremy Yang, Peter Alterovitz, Gil AMIA Jt Summits Transl Sci Proc Articles Traditional cancer classifications are primarily based on anatomical locations. As knowledge is heavily compartmentalized in the oncological specialties, discovering new targets for existing drugs (drug inference) can take years. Furthermore, our lack of understanding of the mechanisms underlying drug efficacy sometimes undercuts the effectiveness of genetic approaches to drug inference. This study tackles the twin problems of cancer reclassification and drug inference by constructing a global cancer ontology inductively from treatment regimens. A topological abstraction algorithm was performed on the bipartite graph of drugs and cancers to highlight important edges, and a Bayesian algorithm was then applied to determine a new treatment-based classification of cancer, producing 6 highly significant clusters (p < 0.05), confirmed by Fisher’s exact test and enrichment analyses. Edge probabilities derived from its drug inference routine matched real edge frequencies (R2 ≈ 0.96). Drug inference results were reinforced by the identification of relevant published Phase II and III clinical trials, and the drug inference routine differentiated between high- and low-likelihood targets (p < 0.05). This novel treatment-based ontology has the potential to reorganize cancer research and provide powerful tools for drug inference using global patterns of drug efficacy. American Medical Informatics Association 2014-04-07 /pmc/articles/PMC4419756/ /pubmed/25954588 Text en ©2014 AMIA - All rights reserved. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose
spellingShingle Articles
Gao, Michael
Warner, Jeremy
Yang, Peter
Alterovitz, Gil
On the Bayesian Derivation of a Treatment-based Cancer Ontology
title On the Bayesian Derivation of a Treatment-based Cancer Ontology
title_full On the Bayesian Derivation of a Treatment-based Cancer Ontology
title_fullStr On the Bayesian Derivation of a Treatment-based Cancer Ontology
title_full_unstemmed On the Bayesian Derivation of a Treatment-based Cancer Ontology
title_short On the Bayesian Derivation of a Treatment-based Cancer Ontology
title_sort on the bayesian derivation of a treatment-based cancer ontology
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4419756/
https://www.ncbi.nlm.nih.gov/pubmed/25954588
work_keys_str_mv AT gaomichael onthebayesianderivationofatreatmentbasedcancerontology
AT warnerjeremy onthebayesianderivationofatreatmentbasedcancerontology
AT yangpeter onthebayesianderivationofatreatmentbasedcancerontology
AT alterovitzgil onthebayesianderivationofatreatmentbasedcancerontology